There’s a long line of middlemen collecting a significant portion of what you pay for medicine.

Hospitals, health insurers, pharmacy benefit managers, the government and others got nearly 50% of what was spent on brand medicines in 2018, up from 33% five years prior.

Since 2015, the amount innovative biopharmaceutical companies received from the sale of brand medicines increased, on average, 2.6% annually, in line with inflation.

Policymakers can’t help patients afford their medicine if they ignore where almost half the money is going.

You don’t know the half of it.